{"id":507400,"title":"Notice: Prescription Drug List (PDL): Multiple additions [2018-03-12] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-02-15","captureTimestamp":"2026-02-15T02:30:51.841000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-multiple-additions-20.html","snippet":"Notice: Prescription Drug List (PDL): Multiple additions March 12, 2018 Our file number: 18-102696-288 The purpose of this Notice of Amendment is to notify about the additions of avelumab, dupilumab, guselkumab, lifitegrast, lotilaner, olaratumab, sebelipase alfa, semaglutide,…","rawSnapshotUrl":"/api/snapshots/raw/507400","browseUrl":"https://replay.healtharchive.ca/job-6/20260215023051/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-multiple-additions-20.html#ha_snapshot=507400","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}